

**RESEARCH UPDATE**
**Dave Storms, CFA**
[dave@stonegateinc.com](mailto:dave@stonegateinc.com)

214-987-4121

**Market Statistics** in USD

Price	\$	0.40
52 week Range	\$0.08 - \$3.12	
Daily Vol (3-mo. average)	109,016,137	
Market Cap (M)	\$	37.5
Enterprise Value (M)	\$	32.4
Shares Outstanding: (M)		93.7
Float (M)		89.9
Public Ownership		88.6%
Institutional Ownership		7.5%


**Financial Summary** in USD

Pro Forma Cash (M)	\$	50.0
Cash/Share	\$	0.53
Debt (M)	\$	1.7
Equity (M)	\$	7.4
Equity/Share	\$	0.27

**FYE: Jun**      **2024**      **2025E**      **2026E**
*(all figures in M, expect per share information)*

EBITDA	\$	(18.4)	\$	(21.0)	\$	(34.0)
Net Income	\$	(18.5)	\$	(21.0)	\$	(34.0)
EPS	\$	(1.15)	\$	(0.96)	\$	(1.56)

EV/R&D	2.9x	1.6x	1.1x
EV/EBITDA	-2.0x	-0.7x	-1.0x
P/E	-2.6x	-0.4x	-0.3x


**Company Description**

Incannex Healthcare, Inc. is a clinical-stage biopharmaceutical development company focused on developing innovative medicines for patients living with chronic diseases and significant unmet need. Incannex is advancing proprietary, synthetic first- and best-in-class cannabinoid and psychedelic-assisted therapeutics targeting sleep apnea, anxiety, and inflammatory diseases. Incannex's lead programs include IHL-42X for the treatment of obstructive sleep apnea (OSA), Psi-GAD in development to assess the use of psilocybin-assisted therapy for generalized anxiety disorder (GAD), and IHL-675A in Phase 2 trials for rheumatoid arthritis (RA). Each of these programs target conditions for which there are either no approved treatments or the available treatments are inadequate.

**INCANNEX HEALTHCARE INC. (NASDAQGM: IXHL)**
**Company Summary**

**IHL-42X Top-Line Results:** Recently IXHL has made significant progress on its IHL-42X asset after very positive topline results from the Phase 2 study have returned, with more granular data trickling in. Both the low and high dose groups achieved a statistically significant reduction in percentage change in Apnoea-Hypopnoea Index (AHI) from baseline compared to placebo. With AHI being the primary indicator of success, we are excited by the phenomenal top line results with maximum AHI reductions of up to 83% for the high-dose group and up to 79% for the low-dose group. In addition to this effectiveness, IHL-42X was tolerated well across both cohorts, having no serious adverse events reported during the treatment period. Lastly, the patient reported outcomes were equally impressive as 57.6% of participants reported a perceived improvement in their OSA, and 89.5% of those reporting improvement described the change as meaningful to their lives. This positions IXHL favorably as it begins the next steps of bringing IHL-42X to market.

**IHL-42X Next Steps:** As mentioned below, the Company is in an extremely favorable position due to its vastly improved capital structure and balance sheet. We believe IXHL has sufficient liquidity to bring IHL-42X to commercial readiness. In the short term we expect more news to become available as more clinical data is analyzed with the help of the expanded advisory board. We also expect that IXHL will have a meeting with the FDA prior to beginning Phase 3. Given the strong phase 2 results it is expected that the Company will continue to evaluate future commercialization at the same time.

**Financing and Capital Structure Update:** IXHL has significantly strengthened its financial position through strategic financing arrangements designed to optimize capital structure and minimize dilution related to its Series A Warrants. Utilizing proceeds from the Company's ATM, IXHL has issue a total of ~\$24.7M worth of shares to repurchase all outstanding Series A Warrants representing 347.2M shares that could be dilutive. These measures highlight management's proactive approach to capital management, supporting the Company's financial flexibility and providing a significant amount of visibility as investors await phase 2 top-line data.


**PSX-001 and IHL-675A Update:** IXHL's PSX-001, a psilocybin-based candidate for Generalized Anxiety Disorder (GAD), successfully achieved positive results from a Phase 2 proof-of-concept study. The Company has secured IND clearance from the FDA and Clinical Trial Authorization from the UK regulatory authorities for the PsiGAD2 Phase 2 trial, which will recruit 94 patients across the U.S. and U.K. Meanwhile, IHL-675A, targeting inflammation associated with rheumatoid arthritis, completed patient dosing in its Phase 2 trial with approximately 128 participants. Data from this study is expected in the second half of 2025, with future resources dedicated to a larger U.S. Phase 2 study, potentially accelerating its regulatory approval.

**Valuation:** We use a probability-adjusted Discounted Cash Flow Model when valuing IXHL. Our valuation model returns a valuation range of \$1.05 to \$2.86 with a midpoint of \$1.70 based on a discount rate range of 12.50% to 17.25% and a current risk adjustment range of 13% to 18%. Further details on our model can be found on page 5 of this report. We note that this model is highly levered to the out years due to the long term nature of IXHL's industry, leading to the potential for dramatic re-ratings as new information becomes available.

## Business Overview

Incannex Healthcare, Inc. (“the Company”, “Incannex”, or “IXHL”) is a clinical-stage biopharmaceutical development company focused on developing innovative medicines for patients living with chronic diseases and significant unmet need. Incannex is advancing proprietary, synthetic first- and best-in-class cannabinoid and psychedelic-assisted therapeutics targeting sleep apnea, anxiety, and inflammatory diseases. Incannex’s lead programs include IHL-42X for the treatment of obstructive sleep apnea (OSA), PSX-001 in development to assess the use of psilocybin combined with psychological therapy for generalized anxiety disorder (GAD), and IHL-675A in Phase 2 trials for rheumatoid arthritis (RA). Each of these programs target conditions for which there are either no approved treatments or the available treatments are inadequate. In 2023 IXHL re-domiciled from Australia to Delaware, with a continued listing on NASDAQ under the ticker symbol “IXHL”.

### Exhibit 1: Company Overview



Source: Company Reports

Incannex has a diversified portfolio of 28 drug candidates backed by 29 granted patents and 32 pending patents that have established proof of concept for under-met medical conditions with significant addressable markets. Of the 28 candidates IXHL is focused on Obstructive Sleep Apnea, Rheumatoid Arthritis, and Generalized Anxiety Disorder. We are encouraged by the diversification in IXHL’s portfolio and note that this portfolio is further de-risked as IXHL is using the FDA’s 505(b)(2) pathway to accelerate the approval process for its OSA and rheumatoid arthritis treatments. This diversification combined with the Company’s focus on commercialization of its assets helps IXHL stand out compared to peers.

### Exhibit 2: Asset Overview

Clinical Project	Addressable Market Opportunity (\$n US\$)	Stage of Development	Regulatory Stage of Development	Next Steps	Relevant Patents
<b>1. Lead Candidates</b>					
IHL-42X Obstructive Sleep Apnea	\$8,345 (\$1.2) by 2024 (6)	Phase 3/3 underway	Phase 3/3 trial completed	IND opening study	16x Pending Key claims deemed novel and inventive
IHL-675A Rheumatoid Arthritis	\$60.1B (\$1.5) in 2021 (2)	Phase 2 completed	FDA Pre-IND completed	Complete phase 2 CT	16x Pending Key claims deemed novel and inventive
Pre-GAD Generalized Anxiety Disorder	\$1.6B U.S. in 2023 (4)	Phase 3A	FDA IND submission	Complete phase 3/3	Provisional patents filed
<b>2. Secondary Assets</b>					
IHL-675A Inflammatory Bowel Disease	\$21B (\$1.5) in 2021 (6)	Pre-clinical completed	FDA Pre-IND completed	Commence phase 2 CT	16x Pending Key claims deemed novel and inventive
APR-1901 Osteoporosis	\$0.1B (Global) in '21 (8)	Phase 2 completed	Pre-IND drafting	Phase 1	1x Granted 1x Pending
APR-1902 Skin Treatment	\$0.1B (Global) in '21 (8)	Phase 3A completed	Pre-IND drafting	Phase 1	2x Pending
APR-1903 Skin Acne Dermatitis	\$1.1B (Global) in '21 (8)	Phase 3A completed	Pre-IND drafting	Phase 1	1x Granted 1x Pending
Canvaxil Addiction: Tobacco Smoking Cessation	\$41,750 (Global) by '24, 11,236 CAD\$ (6)	Pre-clinical	Pre-regulatory	Phase 1	3x Granted
Canvaxil O Addiction: Opioid Addiction	\$64B (\$1.5) in '21 (2)	Pre-clinical	Pre-regulatory	Phase 1	2x Granted

(1) First & Future Market Report as commissioned by APRN, Sept 2020, market opportunity in Inhaled Systemic Opioids  
(2) First & Future Market Report as commissioned by APRN, Sept 2020, market opportunity in combination and other, when other market is not specified, is not specified  
(3) First & Future Market Report as commissioned by APRN, Sept 2020, market opportunity in Addictive Substance Abuse  
(4) First & Future Market Report, "Smoking Cessation and Related Therapeutic Products Market", May 2017  
(5) First & Future Market Report, "Smoking Cessation and Related Therapeutic Products Market", May 2017  
(6) First & Future Market Report, "Smoking Cessation and Related Therapeutic Products Market", May 2017  
(7) First & Future Market Report, "Smoking Cessation and Related Therapeutic Products Market", May 2017  
(8) First & Future Market Report, "Smoking Cessation and Related Therapeutic Products Market", May 2017

Source: Company Reports

Incannex re-domiciled from Australia to Delaware in 2023 with a listing on the NASDAQ. We view the story as having potential for improved exposure leading to improved liquidity and a potential price re-rating. Currently the Company does not have revenues but does receive significant tax incentives from the Australian government for research and development activities which typically amounts to refundable tax offsets for R&D activities equal to approximately 43.5% of R&D activities in the year. Financing of company operations has historically been through equity issuance. To date the Company has not had issues raising funds for operations and we do not have any current concerns that the Company will be unable to finance future operations.

Assets

IHL-42X

IHL-42X is a novel treatment designed to treat people suffering from Obstructive Sleep Apnea (OSA) which is characterized by interrupted breathing while asleep. OSA is a highly prevalent condition where current treatments have poor patient compliance and no approved pharmacotherapies. What makes IHL-42X interesting is its unique combination of dronabinol and acetazolamide, addressing two different physiological aspects of OSA. Dronabinol binds to cannabinoid receptors, modulates signaling, and activates muscles that dilate the airway whereas acetazolamide induces metabolic acidosis which signals to the body that there is excess CO2 in the blood, inducing the taking of a breath. Both of these compounds have been approved in the US for other treatments, leading to the potential reduced timeline to market.

**Exhibit 3: IHL-42X Clinical Development Status**



Source: Company Reports

Currently, IHL-42X has received top line data for its Phase 2 study. Planning for the Phase 3 portion is underway and will be conducted exclusively in the U.S., enrolling approximately 440 patients across multiple sites, including those continuing from Phase 2. Incannex is preparing for an end-of-Phase 2 meeting with the FDA to outline regulatory next steps toward a potential 505(b)(2) NDA submission. Should IHL-42X receive approval, it would enter a significant addressable market, currently valued at approximately \$8.2 billion and primarily dominated by sleep apnea devices such as positive airway pressure (PAP) machines. Given the compliance challenges associated with existing device therapies, there is a considerable opportunity for pharmaceutical solutions like IHL-42X that offer effective, less intrusive treatment options.

**Exhibit 4: IHL-42X Market Overview**




Source: Company Reports

Top line results for the Phase 2 Study are very positive. Both the low and high dose groups achieved a statistically significant reduction in percentage change in Apnoea-Hypopnoea Index (AHI) from baseline compared to placebo. With AHI being the primary indicator of success, we are excited by the phenomenal top line results with maximum AHI reductions of up to 83% for the high-dose group and up to 79% for the low-dose group. In addition to this effectiveness, IHL-42X was tolerated well across both cohorts, having no serious adverse events reported during the treatment period. Lastly, the patient reported outcomes were equally impressive as 57.6% of participants reported a perceived improvement in their OSA, and 89.5% of those reporting improvement described the change as meaningful to their lives. This positions IXHL favorably as it begins the next steps of bringing IHL-42X to market.

PSX-001

PSX-001 is Incannex’s psilocybin drug is designed for use with psychological therapy to treat people suffering from Generalized Anxiety Disorder (GAD) which is characterized by its diffuse, excessive, uncontrollable worry that is not restricted to any specific environmental circumstances. Treatment of GAD remains inadequate, with less than half of patients achieving remissions with currently accepted treatments. What makes Psi-GAD interesting is its use of psilocybin to facilitate access to fundamental causes of anxiety, and providing a remarkable opportunity for patients to make real and lasting changes via psychotherapy.

**Exhibit 3: Psi-GAD2 Treatment Timeline**



Source: Company Reports

Generalized Anxiety Disorder is a highly prevalent disorder, with an estimated 7 million people in the US and 1 million people in Australia having moderate to severe GAD. To study the effectiveness of PSX-001 the primary endpoint is a change in the patients’ anxiety score (HAM-A) 2 weeks following the second dosing session, as compared to the baseline. Currently the Company is planning a trial across 94 patients across 8 sites in the UK and US across 2 patient arms. Results from a completed Therapeutics Goods Administration (TGA) Phase 2 trial conducted in Australia (PsiGAD1) are meaningful with clinical response scores that are four times higher than the placebo group.

The Company reported positive topline results from the PsiGAD1 Phase 2 proof-of-concept trial and anticipates initiating the PsiGAD2 Phase 2 trial, enrolling 94 patients across sites in the U.S. and U.K.

**Exhibit 4: Psi-GAD Clinical Development Status**



Source: Company Reports

IHL-675A

IHL-675A is a novel treatment designed to treat people suffering from inflammation, which is a major contributing factor to rheumatoid arthritis, with many patients not responding to current drug treatments. IHL-675A targets two components of the inflammatory pathway by combining two anti-inflammatory drugs, CBD and hydroxychloroquine sulfate (HCQ). Incannex has demonstrated that IHL-675A reduced disease severity in an animal model of rheumatoid arthritis to a greater extent than either CBD or hydroxychloroquine sulfate alone. HCQ and CBD seem to work synergistically to inhibit production of inflammatory cytokines.

The addressable market for this rheumatoid arthritis treatment is estimated at \$60.1B. The Company recently completed patient dosing in a Phase 2 clinical trial involving approximately 128 subjects and expects to report top-line data in the second half of 2025, with plans to pursue a larger Phase 2 study in the U.S.

### Exhibit 5: IHL-675A Clinical Development Status



Source: Company Reports

### Additional Assets

Additional assets include cannabinoid chewables designed to treat addiction. Incannex holds multiple patents for chewable cannabinoid-based drug candidates that also contain nicotine or opioid agonists and/or antagonists. Opioid use disorder has an estimated addressable market of \$4.59B, and the nicotine chewing gum market was \$5.2B in 2020.

The Company is also working to use a combination of CBD and CBG to treat dermatological conditions caused by disorders of the immune system that include vitiligo, psoriasis and atopic dermatitis, otherwise known as eczema. There is no topical cannabinoid products that have achieved regulatory approval for any skin condition, giving the Company access to the \$1.2B Vitiligo market, the \$26.4B psoriasis market, and the \$11.8B atopic dermatitis market. Patents are pending for compositions and methods of use for treatment of these skin conditions with the next steps being Phase 2 clinical trials in Australia.

### Risks

As with any investment, there are certain risks associated with Incannex's operations as well as with the surrounding economic and regulatory environments common to the pharmaceutical industry.

- The Company has no history of net income, dividends, or cash flow and there can be no assurance that the Company will be profitable going forward. In the case that the Company cannot create enough revenue to sustain on-going business activities, the Company's most likely source of financing will be through the sale of existing securities or high-cost borrowing.
- Currently the Company has enough funds to sustain it through the foreseeable future and does not pose a going concern risk. We do however recognize that the Company will most likely need to raise more funds to sustain its operations until it begins revenue generation. Should the Company be unable to raise the necessary funds this would create a going concern risk.
- The Company is subject to regulatory risk as pharmaceutical activities are subject to laws and regulations imposed by local and state government authorities. Any future changes in the laws, regulations, agreements, or judicial rulings could impact the Company's potential portability.
- Should the Company bring any or all of its assets to market, there is no guarantee that a profitable market will exist for those treatments.

## VALUATION SUMMARY

We use a probability-adjusted Discounted Cash Flow Model when valuing IXHL. Our valuation model returns a valuation range of \$1.05 to \$2.86 with a midpoint of \$1.70 based on a discount rate range of 12.50% to 17.25% and a current risk adjustment range of 13% to 18%. Key assumptions in this valuation include the tax incentive rate remaining at 43.5%, a current total market size of approximately 90.2B, a total market size CAGR of 5% over the foreseeable future, and a steadily increasing market capture percentage. Uncertainties that would have a significant impact on this model would be variances in the time to market for any of the three leading drug candidates which would impact the risk rating, the capital needs of IXHL going forward which would impact the shares outstanding, and any changes to market capture due to a number of variables that would influence the Company's revenue potential. We note that this model is highly levered to the out years due to the long term nature of IXHL's industry, leading to the potential for dramatic re-ratings as new information becomes available. Currently we believe the Company will begin revenue generation as early as FY27, with operating profitability beginning in FY31.

## BALANCE SHEET

<b>Incannex Healthcare Inc.</b>						
<b>Consolidated Balance Sheets (\$M)</b>						
<b>Fiscal Year End: June</b>						
<b>ASSETS</b>	<b>FY 2022</b>	<b>FY 2023</b>	<b>FY 2024</b>	<b>Q1 Sep-24</b>	<b>Q2 Dec-24</b>	<b>Q3 Mar-25</b>
Cash and Cash Equivalents	37.5	22.1	5.9	3.6	2.1	6.7
Prepaid Expenses and Other Assets	0.4	0.9	0.5	0.5	0.4	0.4
R&D Tax Incentive Receivable	-	-	9.8	11.1	1.4	7.1
Assets pledged as security for short-term debt	-	-	-	-	6.6	1.4
<b>Total Current Assets</b>	<b>37.9</b>	<b>23.0</b>	<b>16.2</b>	<b>15.2</b>	<b>10.5</b>	<b>15.6</b>
Property, Plant, and Equipment, net	-	0.3	0.5	0.4	0.3	0.3
Operating Lease ROU Assets	-	0.5	0.4	0.4	0.3	0.3
<b>Total Assets</b>	<b>37.9</b>	<b>23.8</b>	<b>17.0</b>	<b>16.0</b>	<b>11.1</b>	<b>16.2</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>						
Trade and Other Payable	2.0	1.7	0.6	1.6	0.8	1.1
Accrued Expenses	-	0.7	4.8	7.5	3.4	4.7
Operating Lease Liabilities, Current	-	0.1	0.2	0.2	0.2	0.2
Short-term debt	-	-	-	-	1.4	1.4
<b>Total Current Liabilities</b>	<b>2.0</b>	<b>2.6</b>	<b>5.6</b>	<b>9.2</b>	<b>5.8</b>	<b>7.4</b>
Operating Lease Liabilities, Non-Current	-	0.4	0.2	0.2	0.2	0.1
Long-term debt	-	-	-	-	2.4	-
Warrant liabilities	-	-	-	-	1.3	1.3
Convertible rights	-	-	-	-	0.5	-
<b>Total Liabilities</b>	<b>2.0</b>	<b>3.0</b>	<b>5.8</b>	<b>9.5</b>	<b>10.1</b>	<b>8.8</b>
Common Stock	-	0.0	0.0	0.0	0.0	0.0
Preferred Stock	-	-	-	-	-	-
Additional Paid-In Capital	94.7	116.3	125.2	125.7	126.4	136.8
Accumulated Deficit	(58.8)	(92.2)	(110.7)	(116.1)	(122.0)	(126.0)
Foreign Currency Translation Reserve	-	(3.3)	(3.3)	(3.0)	(3.4)	(3.5)
<b>Total Parent Net Equity</b>	<b>35.9</b>	<b>20.8</b>	<b>11.2</b>	<b>6.6</b>	<b>1.0</b>	<b>7.4</b>
<b>Total Liabilities and Shareholders' Equity</b>	<b>37.9</b>	<b>23.8</b>	<b>17.0</b>	<b>16.0</b>	<b>11.1</b>	<b>16.2</b>
<b>Liquidity</b>						
Current Ratio	18.8x	9.0x	2.9x	1.6x	1.8x	2.1x
Quick Ratio	0.0x	0.7x	0.8x	0.8x	0.6x	0.5x
Working Capital	35.87	20.45	10.58	5.98	4.66	8.26

Source: Company Reports, Stonegate Capital Partners

INCOME STATEMENT

Incannex Healthcare Inc.																		
Consolidated Statements of Income (in \$M, except per share amounts)																		
Fiscal Year End: June																		
	FY 2021	FY 2022	FY 2023	Q1 Sep-23	Q2 Dec-23	Q3 Mar-24	Q4 Jun-24	FY 2024	Q1 Sep-24	Q2 Dec-24	Q3 Mar-25	Q4 E Jun-25	FY 2025E	Q1 E Sep-25	Q2 E Dec-25	Q3 E Mar-26	Q4 E Jun-26	FY 2026E
Revenue	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.0	\$ 0.0	\$ 0.1	\$ 0.0	\$ -	\$ 0.2	\$ 0.2	\$ 0.2	\$ 0.2	\$ 0.2	\$ 0.2	\$ 0.7
Other Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total Revenues</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>0.0</b>	<b>0.0</b>	<b>0.1</b>	<b>0.0</b>	<b>-</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.7</b>
Research and Development Costs	5.4	9.4	6.3	2.6	2.6	3.3	4.4	12.9	2.9	1.4	2.7	2.7	9.8	7.5	7.5	7.5	7.5	30.0
Acquisition of In-Process R&D	-	-	35.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative	10.3	12.0	8.0	2.3	5.3	4.1	5.4	17.2	3.4	3.6	2.3	4.0	13.3	4.2	4.2	4.2	4.2	16.6
Total Operating Expenses	15.7	21.4	49.7	4.9	8.0	7.4	9.8	30.1	6.3	5.0	5.0	6.7	23.1	11.7	11.7	11.7	11.7	46.6
<b>Operating Income</b>	<b>(15.7)</b>	<b>(21.4)</b>	<b>(49.7)</b>	<b>(4.9)</b>	<b>(8.0)</b>	<b>(7.4)</b>	<b>(9.8)</b>	<b>(30.0)</b>	<b>(6.3)</b>	<b>(5.0)</b>	<b>(5.0)</b>	<b>(6.6)</b>	<b>(22.8)</b>	<b>(11.5)</b>	<b>(11.5)</b>	<b>(11.5)</b>	<b>(11.4)</b>	<b>(45.9)</b>
R&D Tax Incentive	0.8	1.0	0.7	4.1	2.7	1.3	3.3	11.4	0.8	1.0	0.4	1.2	3.4	3.3	3.3	3.3	3.3	13.1
Foreign Exchange Expense	-	-	(0.1)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.3)	0.0	(0.3)	(0.6)	(0.3)	(0.3)	(0.3)	(0.3)	(1.2)
Interest Income	0.0	0.4	0.2	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Interest expense	-	-	-	-	-	-	-	-	-	(0.2)	(0.1)	-	(0.3)	-	-	-	-	-
Change in fair value of convertible rights	-	-	-	-	-	-	-	-	-	(0.2)	-	-	(0.2)	-	-	-	-	-
Change in fair value of warrant liabilities	-	-	-	-	-	-	-	-	-	(0.1)	1.8	-	1.7	-	-	-	-	-
Other Income expense	-	-	-	-	-	-	-	-	-	(1.1)	(1.1)	-	(2.2)	-	-	-	-	-
<b>Profit Before Taxes</b>	<b>(14.9)</b>	<b>(20.0)</b>	<b>(48.8)</b>	<b>(0.7)</b>	<b>(5.2)</b>	<b>(6.0)</b>	<b>(6.4)</b>	<b>(18.4)</b>	<b>(5.4)</b>	<b>(5.9)</b>	<b>(4.0)</b>	<b>(5.7)</b>	<b>(21.0)</b>	<b>(8.5)</b>	<b>(8.5)</b>	<b>(8.5)</b>	<b>(8.5)</b>	<b>(34.0)</b>
Provision for Income Tax	-	-	-	-	-	-	0.0	0.0	-	-	-	-	-	-	-	-	-	-
<b>Net Income</b>	<b>(14.9)</b>	<b>(20.0)</b>	<b>(48.8)</b>	<b>(0.7)</b>	<b>(5.2)</b>	<b>(6.0)</b>	<b>(6.5)</b>	<b>(18.5)</b>	<b>(5.4)</b>	<b>(5.9)</b>	<b>(4.0)</b>	<b>(5.7)</b>	<b>(21.0)</b>	<b>(8.5)</b>	<b>(8.5)</b>	<b>(8.5)</b>	<b>(8.5)</b>	<b>(34.0)</b>
<b>Basic EPS</b>	<b>\$ (1.25)</b>	<b>\$ (1.30)</b>	<b>\$ (3.32)</b>	<b>\$ (0.05)</b>	<b>\$ (0.33)</b>	<b>\$ (0.38)</b>	<b>\$ (0.39)</b>	<b>\$ (1.15)</b>	<b>\$ (0.29)</b>	<b>\$ (0.33)</b>	<b>\$ (0.20)</b>	<b>\$ (0.29)</b>	<b>\$ (0.96)</b>	<b>\$ (0.39)</b>	<b>\$ (0.39)</b>	<b>\$ (0.39)</b>	<b>\$ (0.39)</b>	<b>\$ (1.56)</b>
<b>Diluted EPS</b>	<b>\$ (1.25)</b>	<b>\$ (1.30)</b>	<b>\$ (3.32)</b>	<b>\$ (0.05)</b>	<b>\$ (0.33)</b>	<b>\$ (0.38)</b>	<b>\$ (0.39)</b>	<b>\$ (1.15)</b>	<b>\$ (0.29)</b>	<b>\$ (0.33)</b>	<b>\$ (0.20)</b>	<b>\$ (0.29)</b>	<b>\$ (0.96)</b>	<b>\$ (0.39)</b>	<b>\$ (0.39)</b>	<b>\$ (0.39)</b>	<b>\$ (0.39)</b>	<b>\$ (1.56)</b>
WTD Shares Out - Basic	11.9	15.4	15.4	15.9	15.9	15.9	16.7	16.2	17.6	17.6	19.6	19.6	21.8	21.8	21.8	21.8	21.8	21.8
WTD Shares Out - Diluted	11.9	15.4	15.4	15.9	15.9	15.9	16.7	16.2	17.6	17.6	19.6	19.6	21.8	21.8	21.8	21.8	21.8	21.8

<b>Growth Rate Y/Y</b>																		
Total cost of revenues		36.1%	132.6%	-87.2%	119.4%	103.1%	133.0%	-39.5%	29.3%	-37.2%	-32.5%	-31.0%	-23.2%	84.1%	132.3%	132.9%	73.0%	101.9%
Operating Income		36.1%	132.6%	-87.2%	119.4%	103.1%	132.7%	-39.5%	27.8%	-37.3%	-32.5%	-32.5%	-24.0%	83.6%	129.2%	129.1%	73.9%	100.7%
Pre-Tax Income		34.1%	144.3%	-98.1%	79.6%	68.9%	54.0%	-62.2%	645.5%	12.5%	-34.2%	-11.5%	13.8%	57.2%	44.2%	114.0%	49.1%	62.1%
Net Income		34.1%	144.3%	-98.1%	79.6%	68.9%	54.8%	-62.2%	645.5%	12.5%	-34.2%	-11.9%	13.6%	57.2%	44.2%	114.0%	49.1%	62.1%

Source: Company Reports, Stonegate Capital Partners estimates

## IMPORTANT DISCLOSURES AND DISCLAIMER

- (a) The research analyst and/or a member of the analyst's household do not have a financial interest in the debt or equity securities of the subject company.
- (b) The research analyst responsible for the preparation of this report has not received compensation that is based upon Stonegate's investment banking revenues.
- (c) Stonegate or any affiliate have not managed or co-managed a public offering of securities for the subject company in the last twelve months, received investment banking compensation from the subject company in the last 12 months, nor expects or receive or intends or seek compensation for investment banking services from the subject company in the next three months.
- (d) Stonegate's equity affiliate, Stonegate Capital Partners, "SCP" has a contractual agreement with the subject company to provide research services, investor relations support, and investor outreach. SCP receives a monthly retainer for these non-investment banking services.
- (e) Stonegate or its affiliates do not beneficially own 1% or more of any class of common equity securities of the subject company.
- (f) Stonegate does not make a market in the subject company.
- (g) The research analyst has not received any compensation from the subject company in the previous 12 months.
- (h) Stonegate, the research analyst, or associated person of Stonegate with the ability to influence the content of the research report knows or has reason to know of any material conflicts of interest at the time of publication or distribution of the research report.
- (i) No employee of Stonegate has a position as an officer or director of the subject company.

**Ratings** - Stonegate does not provide ratings for the covered companies.

**Distribution of Ratings** - Stonegate does not provide ratings for covered companies.

**Price Chart** - Stonegate does not have, nor has previously had, a rating for its covered companies.

**Price Targets** - Stonegate does not provide price targets for its covered companies. However, Stonegate does provide valuation analysis.

### **Regulation Analyst Certification:**

I, Dave Storms, CFA, hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report.

### **For Additional Information Contact:**

Stonegate Capital Partners, Inc.  
Dave Storms, CFA  
Dave@stonegateinc.com  
214-987-4121

---

Please note that this report was originally prepared and issued by Stonegate for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of Stonegate should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. The information contained herein is based on sources which we believe to be reliable but is not necessarily complete and its accuracy cannot be guaranteed. Because the objectives of individual clients may vary, this report is not to be construed as an offer or the solicitation of an offer to sell or buy the securities herein mentioned. This report is the independent work of Stonegate Capital Partners and is not to be construed as having been issued by, or in any way endorsed or guaranteed by, any issuing companies of the securities mentioned herein. The firm and/or its employees and/or its individual shareholders and/or members of their families and/or its managed funds may have positions or warrants in the securities mentioned and, before or after your receipt of this report, may make or recommend purchases and/or sales for their own accounts or for the accounts of other customers of the firm from time to time in the open market or otherwise. While we endeavor to update the information contained herein on a reasonable basis, there may be regulatory, compliance, or other reasons that prevent us from doing so. The opinions or information expressed are believed to be accurate as of the date of this report; no subsequent publication or distribution of this report shall mean or imply that any such opinions or information remains current at any time after the date of this report. All opinions are subject to change without notice, and we do not undertake to advise you of any such changes. Reproduction or redistribution of this report without the expressed written consent of Stonegate Capital Partners is prohibited. Additional information on any securities mentioned is available on request.